See the published version of this preprint at Substance Abuse Treatment, Prevention, and Policy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Alcohol use disorders (AUD) in tuberculosis patients are complicated with poor compliance to anti-tuberculosis treatment and poor tuberculosis treatment outcomes. However, aggregate data concerning this problem is not available. Therefore, this review aimed to fill the above gap by generating an average prevalence of AUD in tuberculosis patients.
Method: Our electronic search for original articles was conducted in the databases of Scopus, PubMed, and EMBASE, African Index Medicus, and psych-info. Besides, the reference list of selected articles was looked at manually to have further eligible articles for the prevalence and associated factors of AUD in tuberculosis patients. The random-effects model was employed during the analysis. MS-Excel was used to extract data and stata-11 to determine the average prevalence of AUD among tuberculosis patients. A sub-group analysis and sensitivity analysis were also run. A visual inspection of the funnel plots and an Eggers publication bias plot test were checked for the presence of publication bias.
Result: A search of the electronic and manual system resulted in 1970 articles. However, after removing duplicates and unoriginal articles, only 28 articles that studied 30854 tuberculosis patients met the inclusion criteria. The average estimated prevalence of AUD in tuberculosis patients was 30% (95% CI: 24.00, 35.00). This was with a slight heterogeneity (I2 = 57%, p-value < 0.001). The prevalence of AUD in tuberculosis patients was higher in Asia and Europe; 37% than the prevalence in the US and Africa; 24%. Besides, the average prevalence of AUD was 39%, 30%, 30%, and 20% in studies with case-control, cohort, cross-sectional and experimental in design respectively. Also, the prevalence of AUD was higher in studies with the assessment tool not reported (36%) than studies assessed with AUDIT. AUD was also relatively higher in studies with a mean age of ≥ 40 years (42%) than studies with a mean age < 40 years (24%) and mean age not reported (27%). Based on a qualitative review; the male gender, older age, being single, unemployment, low level of education and income from socio-demographic variables, retreatment and treatment failure patients, stigma, and medication non-adherence from clinical variables were among the associated factors for AUD.
Conclusion: This review study obtained a high average prevalence of AUD in tuberculosis patients and this varies across continents, design of studies, mean age of the participants, and assessment tool used. This implied the need for early screening and management of AUD in tuberculosis patients.
Keywords
Alcohol use disorder, tuberculosis, Africa
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Substance Abuse Treatment, Prevention, and Policy.
No community comments so far
Editor assigned
On 05 Dec, 2020
Editorial decision: Accept
On 05 Dec, 2020
Submission checks complete
On 05 Dec, 2020
Editor invited
On 05 Dec, 2020
No comments provided
Editor assigned
On 09 Nov, 2020
Reviewers invited
Invitations sent on 09 Nov, 2020
Reviewer #1 agreed
On 09 Nov, 2020
Review #1 received
Received 09 Nov, 2020
Editorial decision: Minor Revision
On 09 Nov, 2020
Submission checks complete
On 09 Nov, 2020
Editor invited
On 09 Nov, 2020
Version 2
Posted 04 Nov, 2020
No comments provided
Review #2 received
Received 29 Oct, 2020
Editorial decision: Minor Revision
On 29 Oct, 2020
Reviewers invited
Invitations sent on 26 Oct, 2020
Reviewer #1 agreed
On 26 Oct, 2020
Reviewer #2 agreed
On 26 Oct, 2020
Review #1 received
Received 26 Oct, 2020
Editor assigned
On 25 Oct, 2020
Submission checks complete
On 24 Oct, 2020
Editor invited
On 24 Oct, 2020
No comments provided
Reviewer #2 agreed
On 21 Oct, 2020
Review #2 received
Received 21 Oct, 2020
Editorial decision: Major Revision
On 21 Oct, 2020
Review #1 received
Received 20 Oct, 2020
Reviewer #1 agreed
On 12 Oct, 2020
Reviewers invited
Invitations sent on 31 Aug, 2020
First submitted
On 31 Aug, 2020
Editor assigned
On 31 Aug, 2020
Submission checks complete
On 30 Aug, 2020
Editor invited
On 30 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Substance Abuse Treatment, Prevention, and Policy.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Substance Abuse Treatment, Prevention, and Policy.
No community comments so far
Editor assigned
On 05 Dec, 2020
Editorial decision: Accept
On 05 Dec, 2020
Submission checks complete
On 05 Dec, 2020
Editor invited
On 05 Dec, 2020
No comments provided
Editor assigned
On 09 Nov, 2020
Reviewers invited
Invitations sent on 09 Nov, 2020
Reviewer #1 agreed
On 09 Nov, 2020
Review #1 received
Received 09 Nov, 2020
Editorial decision: Minor Revision
On 09 Nov, 2020
Submission checks complete
On 09 Nov, 2020
Editor invited
On 09 Nov, 2020
Version 2
Posted 04 Nov, 2020
No comments provided
Review #2 received
Received 29 Oct, 2020
Editorial decision: Minor Revision
On 29 Oct, 2020
Reviewers invited
Invitations sent on 26 Oct, 2020
Reviewer #1 agreed
On 26 Oct, 2020
Reviewer #2 agreed
On 26 Oct, 2020
Review #1 received
Received 26 Oct, 2020
Editor assigned
On 25 Oct, 2020
Submission checks complete
On 24 Oct, 2020
Editor invited
On 24 Oct, 2020
No comments provided
Reviewer #2 agreed
On 21 Oct, 2020
Review #2 received
Received 21 Oct, 2020
Editorial decision: Major Revision
On 21 Oct, 2020
Review #1 received
Received 20 Oct, 2020
Reviewer #1 agreed
On 12 Oct, 2020
Reviewers invited
Invitations sent on 31 Aug, 2020
First submitted
On 31 Aug, 2020
Editor assigned
On 31 Aug, 2020
Submission checks complete
On 30 Aug, 2020
Editor invited
On 30 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Substance Abuse Treatment, Prevention, and Policy.
Background: Alcohol use disorders (AUD) in tuberculosis patients are complicated with poor compliance to anti-tuberculosis treatment and poor tuberculosis treatment outcomes. However, aggregate data concerning this problem is not available. Therefore, this review aimed to fill the above gap by generating an average prevalence of AUD in tuberculosis patients.
Method: Our electronic search for original articles was conducted in the databases of Scopus, PubMed, and EMBASE, African Index Medicus, and psych-info. Besides, the reference list of selected articles was looked at manually to have further eligible articles for the prevalence and associated factors of AUD in tuberculosis patients. The random-effects model was employed during the analysis. MS-Excel was used to extract data and stata-11 to determine the average prevalence of AUD among tuberculosis patients. A sub-group analysis and sensitivity analysis were also run. A visual inspection of the funnel plots and an Eggers publication bias plot test were checked for the presence of publication bias.
Result: A search of the electronic and manual system resulted in 1970 articles. However, after removing duplicates and unoriginal articles, only 28 articles that studied 30854 tuberculosis patients met the inclusion criteria. The average estimated prevalence of AUD in tuberculosis patients was 30% (95% CI: 24.00, 35.00). This was with a slight heterogeneity (I2 = 57%, p-value < 0.001). The prevalence of AUD in tuberculosis patients was higher in Asia and Europe; 37% than the prevalence in the US and Africa; 24%. Besides, the average prevalence of AUD was 39%, 30%, 30%, and 20% in studies with case-control, cohort, cross-sectional and experimental in design respectively. Also, the prevalence of AUD was higher in studies with the assessment tool not reported (36%) than studies assessed with AUDIT. AUD was also relatively higher in studies with a mean age of ≥ 40 years (42%) than studies with a mean age < 40 years (24%) and mean age not reported (27%). Based on a qualitative review; the male gender, older age, being single, unemployment, low level of education and income from socio-demographic variables, retreatment and treatment failure patients, stigma, and medication non-adherence from clinical variables were among the associated factors for AUD.
Conclusion: This review study obtained a high average prevalence of AUD in tuberculosis patients and this varies across continents, design of studies, mean age of the participants, and assessment tool used. This implied the need for early screening and management of AUD in tuberculosis patients.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
Loading...